Joint Corp (NASDAQ:JYNT) rose 7.7% on Monday . The company traded as high as $2.25 and last traded at $2.23, with a volume of 55,438 shares trading hands. The stock had previously closed at $2.07.

JYNT has been the topic of a number of recent research reports. Maxim Group dropped their price objective on Joint Corp from $8.00 to $5.00 and set a “buy” rating on the stock in a research report on Friday, July 1st. Feltl & Co. downgraded Joint Corp from a “strong-buy” rating to a “buy” rating in a research report on Friday, June 24th. Finally, Zacks Investment Research raised Joint Corp from a “sell” rating to a “hold” rating in a research report on Tuesday, May 17th.

The firm has a 50 day moving average of $2.70 and a 200 day moving average of $3.63. The firm’s market capitalization is $28.26 million.

Joint Corp (NASDAQ:JYNT) last posted its quarterly earnings data on Thursday, May 12th. The company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.02. The company had revenue of $4.30 million for the quarter, compared to analyst estimates of $4.52 million. On average, analysts forecast that Joint Corp will post ($1.01) EPS for the current year.

In other Joint Corp news, major shareholder Glenhill Advisors Llc bought 80,069 shares of the business’s stock in a transaction dated Friday, July 1st. The stock was acquired at an average cost of $1.97 per share, with a total value of $157,735.93. The transaction was disclosed in a filing with the SEC, which is available at this link.

The Joint Corp. develops, owns, operates, supports and manages chiropractic clinics through direct ownership, management arrangements, franchising and the sale of regional developer rights throughout the United States. The Company is franchisor and operator of chiropractic clinics. The Company offers its patients the opportunity to visit its clinics without an appointment and receive prompt attention.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.